ResMed (RMD) has been under the spotlight for a series of significant events. The company's stock rating has been upgraded by both RBC Capital and Mizuho with the latter increasing the price target to $270. ResMed has also witness an insider reducing their stake by 72%. The FY2025 Q4 earnings call date has been announced for investors' note, while the FY2025 Q3 call highlighted robust revenue growth and strategic initiatives from the company. Analysts foresee ResMed as a strong growth stock in the long run, reflected by its eventful past performance in the healthcare sector. The company recently acquired VirtuOx, a virtual diagnostics company, potentially to strengthen its market position. CEO Michael Farrell made a notable sale worth $2.01 million. Other key events include ResMed's mixed earnings causing some investors' concerns, amidst rising competition. However, the company's better than expected sales in Q4 combined with its prudent use of debt seems to balance the prospects. A new patient monitoring stock teardown pits ResMed against the rest. Despite the potential market challenges from a new sleep apnea treatment, an increase in revenue by 10% in Q2 indicates a promising future.
Resmed RMD News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Thu, 17 Jul 2025 14:54:34 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -3
